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Targeted Metabolic Imaging to Improve the
Management of Heart Disease
Moritz Osterholt, CANDMED,* Shiraj Sen, BA,* Vasken Dilsizian, MD,†
Heinrich Taegtmeyer, MD, DPHIL*
ouston, Texas; and Baltimore, Maryland
Tracer techniques are powerful methods for assessing rates of biological processes in vivo. A case in point
is intermediary metabolism of energy providing substrates, a central feature of every living cell. In the
heart, the tight coupling between metabolism and contractile function offers an opportunity for the
simultaneous assessment of cardiac performance at different levels in vivo: coronary flow, myocardial
perfusion, oxygen delivery, metabolism, and contraction. Noninvasive imaging techniques used to iden-
tify the metabolic footprints of either normal or perturbed cardiac function are discussed. (J Am Coll
Cardiol Img 2012;5:214–26) © 2012 by the American College of Cardiology Foundationgy,
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havIn order to contract under constantly changing
environmental conditions, the healthy heart
derives its energy from a variety of oxidizable
organic compounds (1). When myocardial en-
ergy demands are increased acutely, the heart
maintains the balance between its energetic
supply and demand by shifting fluxes through
existing metabolic pathways (2,3). Sustained
increases in myocardial energy demand result in
metabolic adaptations at a transcriptional level
through selective up-regulation of the synthesis
and degradation of the enzymes that collectively
make up metabolic pathways (4). In short, a
striking system of checks and balances regulates
contractile function in the heart and metabolism
is at the center of the whole system.
Since the 1980s, the study of cardiac metab-
olism in the laboratory has been leveraged by
clinicians using noninvasive imaging to distin-
guish heart muscle that is reversibly dysfunc-
tional (viable myocardium) from muscle that is
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assessment of regional myocardial metabolism
was first appreciated as a tool to guide therapeutic
decisions for revascularization in patients with
chronic ischemic left ventricular dysfunction.
Here, the premise was that restoration of blood
flow to viable ischemic tissue will result in resto-
ration of oxidative metabolism and, therefore,
normal contractile function. Similar imaging
techniques are now explored to identify prospec-
tively patients with reversible left ventricular dys-
function in order to improve both quality of life
and outcome (6,7).
Regulation of Metabolism in
Normal and Failing Hearts
The uptake of oxidizable fuel is tightly
matched to the contractile work performed by
the heart (8). Because oxygen extraction by the
heart is nearly complete, increased rates of
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215oxygen consumption can only be met by an increase
in coronary flow (9). The normal heart oxidizes fat
in preference to carbohydrates (the Randle hypoth-
esis) (10), but it increases carbohydrate oxidation
when stressed (11). When myocardial blood flow is
impaired, the balance between cellular metabolism
and contractile function is perturbed. The decrease
in coronary flow and concomitant reduction in
oxygen delivery triggers specific and coordinated
responses in gene expression, including activation of
hypoxia-inducible factor 1-alpha (12) and the reac-
tivation of the fetal gene program (13), both of
which improve the cardiomyocytes’ tolerance to
ischemia. Collectively, these changes represent the
heart’s adaptive processes resulting in cell survival, a
phenomenon that we termed “programmed cell
survival” some time ago (14,15). The term pro-
grammed cell survival contrasts programmed cell
death or apoptosis, which occurs in the maladapted,
failing heart. The metabolic derangements in the
failing heart have been reviewed earlier (16,17). We
have proposed that the nonischemic, failing heart is
drowning in fuel (18), and there is considerable
metabolic heterogeneity in the failing human heart.
Both are areas of active research and beyond the
scope of this review.
Beyond supporting the metabolism of energy-
providing substrates, proteins that regulate meta-
bolic pathways in the heart turn over themselves, as
do sarcomeric proteins, cytoskeletal proteins, and
other cellular components that are necessary for
cardiac maintenance and growth. When subjected
to stress, the heart undergoes hypertrophy, a process
that demands increased energy supply. A large
amount of this energy is likely required to fuel
protein synthesis and protein quality control (19),
suggesting the need for the cardiomyocyte to con-
tinually renew itself from within during times of
growth. Whereas regression of left ventricular hy-
pertrophy has been associated with improved con-
tractile function, its effects on myocardial energetics
have yet to be characterized with noninvasive met-
abolic imaging.
Which Tracers for Which Pathways?
Nuclear metabolic imaging uses targeted radiotrac-
ers to assess flux through specific metabolic path-
ways (by quantifying either the flux of energy-
providing substrates or the steady-state metabolites). It
is convenient to follow energy transfer in the heart
muscle cell from the circulation (substrate and
oxygen delivery) to the cross bridges (energy use)through a series of moiety-conserved cycles (Fig. 1).
Specific radiotracers are available to assess perfu-
sion, substrate uptake, and delivery, as well as Krebs
cycle turnover (oxygen consumption). We have
represented the family of radiolabeled tracers by red
arrows. In addition, we have highlighted the met-
abolic imaging modalities by magnetic resonance
spectroscopy with either stable isotopes (e.g., car-
bon C 13) or phosphorous P 31 in the blue circles.
Calcium (Ca2) is not an imaging agent, but the
ion has been included because it is the signal that
links contraction and mitochondrial respiration
(20). Radiotracer retention and/or metabolism are
assessed by noninvasive techniques, such as single-
photon emission computed tomography (SPECT)
and positron emission tomography (PET).
Two classes of radiotracers are currently
used to trace metabolic activity: labeled
substrates or substrate analogs. Labeled
substrates are taken up by heart muscle
and either rapidly cleared or retained,
whereas substrate analogs are taken up and
retained only (Fig. 2). Both will be dis-
cussed in the context of their usefulness.
To assess fatty acid use, earlier studies
used the labeled substrate carbon C 11
(11C)–palmitate. After its uptake into the
ell and activation by binding to coenzyme
, 11C-palmitate undergoes beta-oxidation,
ltimately leading to the release of 11CO2.
However, this technique requires a PET
camera and an on-site cyclotron. As SPECT
cameras were already available to the major-
ity of nuclear cardiologists, the focus turned
on the development of SPECT tracers for
fatty acid oxidation. One of them is iodine I
123–beta-methyl-p-iodophenyl-pentadeca-
noic acid (123I-BMIPP), a substrate ana-
log that is rapidly taken up into the cardi-
omyocytes and that shows prolonged retention due
to limited catabolism.
The current gold standard for evaluating glucose
metabolism is 2-deoxy-2-(18F) fluoro-D-glucose
(18F-FDG) PET. 18F-FDG is a glucose analog that
competes with glucose for phosphorylation by hexoki-
nase. Once phosphorylated, it is trapped inside the cell
and can neither be further metabolized, nor exported
back out of the cell. We have demonstrated previously
(21) the retention of 18F-FDG in the isolated per-
used heart at a constant, intermediate workload (Fig. 3).
Hearts were perfused with a buffer containing
18F-FDG for 60 min. During this time, radioactiv-
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216the retention of the tracer by the heart when the
perfusate was switched to a tracer-free perfusate at
60 min (Fig. 3, arrow). The drop in tissue radioac-
tivity was caused by the washout of tracer from the
ventricles and vascular and extracellular spaces.
Energy Is Transferred Along a Series of Conserved Cycles,
t Coronary Circulation and Ending at Cross-Bridge Formation
tile Elements
lease from the sarcoplasmic reticulum triggers calcium uptake
itochondria and activation of dehydrogenases in the Krebs cycle.
ed tracers in combination with single-photon emission computed
y or positron emission tomography (red arrows) and nuclear
esonance spectroscopy (blue cycles) can assess various cycles
ely in vivo. ATP  adenosine triphosphate; NAD(P)H/H 
icotinamide adenine dinucleotide (phosphate); FADH2  reduced
ine dinucleotide; PCr  phosphocreatine.
Schematic Overview of the Fate of Labeled Substrates and
Analogs
ed carbon C 11 (11C) substrate is taken up into the cell and
complete oxidation, eventually leading to the release of 11CO2.
uptake into the cell, substrate analogs labeled with ﬂuorine F 18
ine I 123 (123I) are partially metabolized and then retained. The
f perfusion tracers require preserved cellular metabolism to be
y the cell. Substrate oxidation rates can also be monitored using
15 1515 ( O) and measuring the release of H2 O.Also, note that tracer uptake was linear with time by
Patlak analysis (Fig. 3, see inset).
Whereas the imaging of glucose and fatty acid
metabolism in the heart has been well established in
the past, imaging of amino acid metabolism has
received less attention. In comparison to fatty acids
and carbohydrates, amino acids are a more heteroge-
neous group of small organic compounds. The func-
tion of amino acids as building blocks for proteins and
the intermediary metabolism of amino acids in the
body was first investigated with stable isotopes by
Schoenheimer in 1942 (22). The carbon skeleton of
amino acids may enter the citric acid cycle and
replenish the pool of its intermediates by a process
termed anaplerosis, or be used for anaerobic energy
provision (23). In 1954, Bing et al. (24) reported that
amino acids were extracted from the coronary blood
and suggested that “a considerable fraction of the
oxygen consumption of the heart can be ascribed to
the breakdown of amino acids.” The intermediary
metabolism of amino acids is complex. However,
under aerobic conditions many amino acids, including
the branched chain amino acids (BCAA) leucine,
isoleucine, and valine, are oxidized in the Krebs cycle
(Fig. 1). The BCAA are essential amino acids with
multiple roles in energy balance, nutrient signaling,
and protein homeostasis (25). The rate-limiting step
in their catabolism is the alpha-ketoacid dehydroge-
nase reaction, an enzyme regulated by phosphoryla-
tion and dephosphorylation (26). Huang et al. (27)
recently reviewed the role of defects in BCAA me-
tabolism in heart disease. Despite the physiological
importance of BCAA metabolism (and myocardial
protein turnover in general), as yet no metabolic
imaging strategies have been applied in the heart.
In contrast, amino acid metabolism in the ische-
mic heart has been investigated with 11C-
glutamate. The rationale for this tracer is given by
the anaerobic metabolism of glutamate to both
alanine (28) and succinate (23). At the same time,
we observed enhanced extraction of glutamate and
enhanced release of alanine by hearts of patients
with coronary artery disease (29). We suggested
that this pattern was part of an adaptive process,
where pyruvate is converted into alanine by the
transfer of an amino group from glutamate, thereby
reducing the formation of lactate out of pyruvate,
which would ultimately inhibit glycolysis and thus
anaerobic adenosine triphosphate production. Al-
though the potential of using labeled amino acids
for cardiac PET imaging was recognized 30 years
ago (30), only a few investigators have used thisFigure 1.
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217ischemia. Several studies have assessed the uptake
of nitrogen N 13 glutamate in the ischemic heart,
reporting either increased (31,32) or unchanged
rates of uptake (33), relative to blood flow tracers as
nitrogen N 13 ammonia or thallium Tl 201 (201Tl).
More recent studies used 11C-methionine for PET
nalysis of cardiac tissue after myocardial infarction
MI) (34). The investigators reported increased
ptake of 11C-methionine in infarcted areas during
the acute phase after MI, whereas 201Tl and 18F-
FDG uptake were reduced. Thus, the assessment of
11C-methionine uptake can be useful in monitoring
the remodeling of the heart after MI. With the
current notion that changes in amino acid metab-
olism are an “underappreciated culprit” of heart
disease, rather than just an epiphenomenon (27),
studies addressing and validating the imaging of
cardiac amino acid metabolism by using labeled
amino acids are needed more than ever.
Metabolic Remodeling in MI
The heart protects itself from insufficient oxygen
supply by down-regulating mitochondrial oxidative
metabolism. Moderate ischemia (75% reduction in
coronary flow) shifts myocardial energy metabolism
to an anaerobic state (35). During severe ischemia
(90% reduction in coronary flow), myocardial glu-
cose extraction increases while glucose uptake re-
mains the same (36), at least until the degree of
ischemia becomes so severe that substrate delivery
and glycolysis are both inhibited by the accumula-
Figure 3. Diagram Showing Linear Increase of Radioactivity in t
18F-Fluorodeoxyglucose-Containing Buffer
Note that tissue radioactivity remains constant after a tracer-free bu
experiment (not shown). Patlak analysis shows linear tracer uptaketion of lactate (37). During prolonged severe ische-mia, the decline of glucose uptake may be attenuated
by various interventions protecting the heart against
ischemic injury, such as an increase in the extracellular
glucose concentration or the addition of insulin (38).
Moreover, transcript levels of glucose transporters are
also increased (39–41). In the absence of adaptive
changes in metabolism, the resultant energy deficit
ultimately leads to cell death, either by apoptosis or
necrosis (14). Hence, acute and chronic metabolic
adaptation to a temporary or sustained reduction in
coronary blood flow conserves energy to protect the
structural and functional integrity of the myocardium.
Reversible metabolic changes, as a feature of sustained
myocardial viability, will occur in the setting of dimin-
ished but not absent regional myocardial blood flow.
Assessment of Myocardial Viability
To date, much has already been written about the
assessment of myocardial viability (42). The prin-
ciple is clear. Any transformational change in re-
sponse to an altered environment requires a living
or “viable” tissue. Let us consider the following: As
already outlined, the oxygen-deprived heart exhibits
drastic changes in its metabolism leading to the
development of left ventricular dysfunction. Assess-
ment of myocardial viability is needed in a situation,
when left ventricular dysfunction can be either
permanent (due to myocardial cell death and for-
mation of scar tissue) or reversible (in hibernating
myocardium, which is ischemic but still viable). The
benefit of revascularization for patients with coro-
Heart During Perfusion With
was used (arrow). Cardiac power was unchanged throughout the
time (inset). cps  counts/s.he
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218increased with increasing amounts of hibernating
myocardium (43). Metabolic imaging techniques
such as 18F-FDG PET can identify the extent of
ibernating myocardium and, therefore, help to
ssess the benefit of revascularization in these pa-
ients (44).
By definition, hibernating myocardium shows
hronic contractile dysfunction in the setting of
educed coronary flow reserve. After revasculariza-
ion, myocardial function is restored, paralleled by
n increase in coronary flow reserve (45). Hibernat-
ng myocardium can be assessed noninvasively with
variety of radiolabeled markers using different
echniques. Whereas SPECT tracers, like 201Tl
hloride and technetium Tc 99m (99mTc)–labeled
tetrofosmin and 99mTc sestamibi, are primarily used
to assess blood flow, the uptake and retention of
these agents inside the cell still requires intact cell
membranes and viable cells. Hence, thallium and
99mTc-labeled perfusion tracers can be used for
viability assessment as well. These flow tracers when
administered under resting conditions delineate pres-
ence or absence of scar tissue and its amount. As such,
the information obtained with these flow tracers is
analogous to that available through late contrast-
enhanced magnetic resonance imaging where the
amount of residual nonenhancing myocardium (or
scar tissue) contains, similar to the perfusion defect
severity, predictive information on the potential for
functional recovery (46). However, beyond identifying
regional blood flow, thallium differs from other flow
tracers as being a monovalent cation with biologic
properties that are similar to potassium. Like potas-
sium, thallium is transported across the myocellular
Figure 4. PET Scan Showing Hibernating Myocardium, Revealin
(A) Blood ﬂow imaging using rubidium Rb 82 (82Rb) in short-axis vi
basal slices in the apical, inferior, inferolateral, and septal regions o
cose–(18F-FDG) labeled positron emission tomography images acqu
abnormally perfused myocardium, except for the anteroseptal regio
from Taegtmeyer and Dilsizian (58).membrane via the sodium-potassium adenosine
triphosphatase transport system. Whereas the initial
extraction and distribution of thallium in the myocar-
dium are primarily a function of blood flow, the late
redistribution phase of thallium is a function of re-
gional myocardial potassium space (as the radiotracer
has equilibrated between blood and myocytes). Thus,
differences in thallium distributions between the early
(myocardial perfusion phase) and delayed images re-
flect hypoperfused but viable (in the true sense of the
term) myocardium. At the same time, although myo-
cardium can be severely hypoperfused, regional in-
crease in glucose extraction via glucose transporter
protein type 1 results in up-regulated glucose uptake
(termed a mismatch pattern) (Fig. 4). This mismatch
pattern is an indicator for hibernating myocardium,
which can be salvaged by the restoration of blood flow.
Therefore, metabolic imaging of myocardial viability
may assist the early identification of patients who
would benefit from revascularization therapies. This
would decrease the risk/benefit ratio of revasculariza-
tion and improve the patient’s outcome and prognosis.
Imaging Cardiac Metabolism to
Detect Antecedent Ischemia
The detection of even subtle metabolic alterations in
the ischemic myocardium by metabolic imaging was
first shown in a canine model of partial coronary artery
occlusion and rapid atrial pacing (47). In subsequent
occlusion-reperfusion studies, prolonged metabolic al-
terations were observed after 30 min of occlusion.
These metabolic changes persisted for several weeks
thereafter (48–51). The studies served as the experi-
rfusion-Metabolism Mismatch
shows markedly decreased perfusion, extending from distal to
left ventricle at rest. (B) Fludeoxyglucose F 18 ﬂuorodeoxyglu-
under glucose-loaded conditions show preserved glucose use in
which metabolism matches perfusion. Adapted, with permission,g Pe
ew
f the
ired
n, in
t
a
(
a
t
s
g
e
e
p
r
a
o
f
d
d
(
t
p
p
w
r
S
t
t
a
m
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 2 , 2 0 1 2
F E B R U A R Y 2 0 1 2 : 2 1 4 – 2 6
Osterholt et al.
Imaging to Improve the Management of Heart Disease
219mental basis of subsequent clinical studies in which
persistent reductions in fatty acid metabolism could be
detected long after the resolution of the perfusion
abnormality and ischemia (52–58). Thus, the applica-
tion of a metabolic radiotracer for imaging, as opposed
to a perfusion tracer, potentially extends the scope for
noninvasive imaging of an ischemic event beyond the
resolution of symptoms and allows monitoring long-
term effects. The concept applies to tracers or tracer
analogs of both long-chain fatty acids and glucose.
Their uptake by previously ischemic heart muscle is
either decreased (in the case of fatty acids) or increased
(in the case of glucose).
An exciting development in this field is the use of
123I-BMIPP to assess fatty acid metabolism with
SPECT. In an open-label phase 2A clinical trial,
patients with exercise-induced ischemia on a clini-
cally indicated thallium SPECT study underwent
rest 123I-BMIPP SPECT imaging within 30 h of
he exercise treadmill study (52). 123I-BMIPP was
ble to detect antecedent ischemic abnormality
with 91% agreement between 123I-BMIPP uptake
nd retention under resting conditions and 201Tl
imaging under stress conditions). These findings
were complemented by studies that interrogated the
benefits of assessing altered glucose metabolism in
patients undergoing exercise treadmill testing using
18F-FDG (53,54). A metabolic switch from pre-
dominant fatty acid use to predominant glucose use
seems pivotal in preserving myocardial viability and
likely represents the earliest adaptive response to
myocardial ischemia (53). Applying a dual-isotope
99mTc sestamibi and 18F-FDG simultaneous injec-
ion and acquisition protocol, investigators have
hown that a metabolic switch from fatty acid to
lucose use occurs promptly when myocardial isch-
mia is induced during exercise. Moreover, the
xercise-induced metabolic switch to glucose may
ersist for 24 h, despite restoration of blood flow at
est (54,55). Together, these reports with fatty acid
nd glucose analogues suggest an interdependence
f the increased glucose uptake and the diminished
atty acid uptake. Whether there are temporal
ifferences between the 2 processes cannot be ad-
ressed conclusively, because the 2 radiotracers
123I-BMIPP and 18F-FDG) were not injected at
he same time and in the same patient.
In a recent multicenter clinical trial, patients
resenting to the emergency department with sus-
ected acute coronary syndrome were imaged with
123I-BMIPP within 30 h of symptom cessation
(56). The initial clinical diagnosis was based on
symptoms, electrocardiographic changes, and ele-vated serum troponin levels, whereas the final di-
agnosis was determined on the basis of all available
data (including coronary angiography and stress
SPECT) but not 123I-BMIPP SPECT. Final di-
agnoses were adjudicated by a blinded committee
into “positive for acute coronary syndrome,” “inter-
mediate likelihood of acute coronary syndrome,” or
“negative for acute coronary syndrome.” Compared
to the clinical impression alone, the combination of
123I-BMIPP with the initial clinical diagnosis in-
creased sensitivity for identifying patients with
acute coronary syndrome, negative predictive value,
and positive predictive value, with the same speci-
ficity. The findings suggest that the addition of
123I-BMIPP imaging data to the clinical impression
provides incremental value toward the early diag-
nosis of acute coronary syndrome in the emergency
department. These results are consistent with ear-
lier findings in patients with acute chest pain who
underwent coronary angiography, in which the
sensitivity of 123I-BMIPP for detecting an obstruc-
tive coronary artery disease or provocable spasm was
74%, when 123I-BMIPP imaging was carried out
ithin 3 days of presenting symptoms (57). Delayed
ecovery of fatty acid metabolism as assessed by
PECT for up to 30 h after the resolution of
ransient myocardial ischemia, provides the poten-
ial for diagnosing antecedent myocardial ischemia,
phenomenon that we have termed “ischemic
emory” or “metabolic stunning” (58).
Metabolic Remodeling of the Heart in
Diabetes and Obesity
Noninvasive imaging also provides distinct advantages
to studying the effects of systemic metabolic diseases,
such as diabetes and obesity, on the heart. The
introduction of new animal models of insulin resis-
tance and type 2 diabetes has resulted in a deeper
understanding of the biochemical derangements un-
derlying metabolic and structural remodeling of the
myocardium. We have proposed that metabolic re-
modeling precedes, triggers, and maintains functional
and structural remodeling, all of which can be traced
by noninvasive imaging techniques (2). With diabetes
and obesity, fatty acid delivery to the heart is in-
creased. In combination with increased incorporation
of fatty acid translocase into the plasma membrane
(59), excess fatty acid supply results in increased
intracellular levels of fatty acids. After being activated
to acyl coenzyme A, fatty acids can serve many
purposes, including energy production (via mitochon-
drial beta-oxidation), post-translational protein mod-
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220ification, or triglyceride synthesis (60). However, car-
diomyocytes have only a limited capacity to store
triglycerides and an increase in triglyceride levels in the
heart can be used as an indicator of a deleterious
imbalance between fatty acid uptake and oxidation
(61) that eventually culminates in lipotoxicity. Indeed,
myocardial lipid overload induces a lipotoxic cardio-
myopathy even in the absence of systemic perturba-
tions in fatty acid metabolism (62).
In patients with impaired glucose tolerance, myo-
cardial steatosis was found using hydrogen H 1 mag-
netic resonance spectroscopy and shown to precede
the onset of type 2 diabetes and cardiac dysfunction
(63). Whereas increased intracellular triglyceride levels
are considered more as a marker rather than a medi-
ator of lipotoxicity (64), increased levels of acyl coen-
zyme A have several detrimental effects. 1) Beside
triglycerides, levels of diacylglycerol (DAG) are en-
hanced, which has been implicated in the activation of
protein kinase C theta. Chronic activation of protein
kinase C theta impairs insulin signaling by phospho-
rylating insulin-receptor substrate 1 on serine residues
(65,66). 2) Concentration of ceramide, potentially
cardiotoxic due to its role in apoptotic signaling, is
increased, which is associated with the development of
cardiomyopathies in diabetes and obesity (67).
3) Excess fatty acids and their oxidation are associated
Figure 5. Pathogenic Factors Contributing to the Development
See text for further discussion. Reprinted, with permission, from Dil
LVH  left ventricular hypertrophy.with increased production of reactive oxygen species
that are known to compromise a variety of other
cellular processes and to induce adverse cardiac re-
modeling (68). However, a recent study raises doubt
about the role of DAG and ceramide as mediators of
lipotoxic heart disease. Son et al. (69) assessed meta-
bolic changes in a peroxisome proliferator-activated
receptor-alpha– deficient model of peroxisome
proliferator-activated receptor-gamma–induced car-
diolipotoxicity and reported increased rates of fatty
acid oxidation with preserved cardiac function and
improved survival despite no changes in triglycerides,
DAG, and ceramide levels. This now questions the
biological relevance of these lipotoxic intermediates in
mediating contractile dysfunction.
Metabolic Remodeling in the Heart of Patients With
Pre-Clinical and End-Stage Renal Disease
Whereas MI and ischemic heart disease account for
the significant portion of patients with heart failure
and left ventricular remodeling, several sequelae of
renal failure can also contribute to left ventricular
metabolic remodeling, termed uremic cardiomyopa-
thy (70–72) (Fig. 5). Kidney disease affects over 19
million American adults, and the prevalence of
moderate-to-severe chronic kidney disease (CKD) in
remic Cardiomyopathy in the Setting of CKD
n and Fink (70). CKD  chronic kidney disease;of U
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221individuals who are not on dialysis is high (73). The
United States Renal Data System has reported near-
equivalent rates of MI and cardiac death in dialysis
patients and an approximately 10-fold higher rate of
heart failure in the same population (74). The com-
mon occurrence of heart failure in the dialysis popu-
lation is thought to be related to left ventricular
hypertrophy that occurs frequently in patients with
CKD. Hypertension is common among patients with
renal disease and has been suggested to be volume-
dependent. Therefore, both volume- and pressure-
overload would trigger left ventricular hypertrophy,
whereas further changes in structure (e.g., anterior wall
thickening and arterial stiffening) and hormone status
(i.e., activation of neurohormones) take place. Concom-
itantly, renal function declines and CKD progresses.
The so-called uremic cardiomyopathy probably has
multiple causes. One of them involves a myocyte-
capillary mismatch, with a diminished vascular supply
relative to the number and volume of functioning
myocytes (75). As in the ischemic heart, the oxygen-
poor milieu leads to a decline in aerobic myocardial
fatty acid use and a shift to anaerobic glycolytic
metabolism, with increased uptake of glucose as the
principal energy-providing substrate (76,77). The shift
from a predominance of aerobic (fatty acid) to anaer-
obic (glucose) metabolism appears to account for a
significant portion of the excessive cardiovascular
morbidity and mortality observed across all stages of
kidney disease (70,78). Thus, the application of a
noninvasive, quantitative PET technique to monitor
myocardial metabolism in early-stage kidney disease has
the potential to identify deleterious changes in cardiac
metabolism before its manifestation as contractile dys-
function and cardiac hypertrophy.
Pre-clinical myocardial metabolic alterations in CKD.
18F-FDG PET images are usually interpreted quali-
tatively in areas with myocardial perfusion deficits at
rest and designated as either metabolism-perfusion
mismatch (indicating viable myocardium) or match
(indicating scarred myocardium) defects. However,
detection of early, pre-clinical myocardial metabolic
alterations can be limited with qualitative assessment
of regional 18F-FDG uptake. Although the distribu-
tion of 18F-FDG uptake may visually appear homo-
geneous throughout the left ventricular myocardium,
absolute myocardial glucose use may be abnormal.
Quantitative assessment with PET may identify alter-
ations in whole myocardial glucose uptake (MGU)
before clinical, functional, and prognostic conse-
quences ensue.
The feasibility of employing quantitative MGU
with PET to gain additional insight into the altera- dtions of myocardial metabolism in CKD patients was
recently studied (77). The investigators demonstrated
a significant inverse correlation between myocardial
glucose uptake and renal function, assessed by esti-
mated glomerular filtration rate, in CKD patients.
The relationship between MGU and estimated glo-
merular filtration rate could not be ascribed to demo-
graphic factors or cardiac workload. Thus, 18F-FDG
ET may be an effective tool to investigate pre-clinical
hanges in myocardial metabolism in CKD.
Myocardial metabolic alterations in end-stage CKD. In
emodialysis patients without coronary artery dis-
ase, investigators have demonstrated alterations in
yocardial fatty acid use in subsets of patients by
sing 123I-BMIPP SPECT. Reduced uptake of
123I-BMIPP correlates with reduced left ventricular
ejection fraction and increased systemic insulin
resistance (76). Whereas some studies have demon-
strated that systemic insulin resistance is associated
with heart failure and cardiac insulin resistance
(79), others have argued that it does not (80). The
importance of assessing metabolic changes in the
heart of patients with end-stage CKD was, how-
ever, underlined by another study where impaired
123I-BMIPP uptake was shown to identify patients
with a high risk for cardiac death (78). The appli-
cation of metabolic imaging with PET and SPECT
tracers has the potential to offer useful insights into
the pathogenesis for uremic cardiomyopathy and to
point toward therapies for this disease. For exam-
ple, carnitine deficiency is known to be common in
end-stage renal disease and supplementation to
patients on dialysis has been evaluated as a potential
treatment for heart failure and hypotension (81). At
least 1 study has used SPECT to examine the effect
of carnitine supplementation on free fatty acid
metabolism in patients with end-stage renal disease
(82). The study demonstrated enhanced washout of
myocardial 123I-BMIPP with carnitine treatment
but no change in the heart-to-mediastinal ratio.
The relatively preserved heart-to-mediastinal 123I-
MIPP uptake in the chronic hemodialysis patients
uggests that the myocardial adenosine triphos-
hate content in these patients (hence adenosine
riphosphate– dependent conversion of 123I-
MIPP to 123I-BMIPP coenzyme A) had not
ecreased in these patients despite carnitine defi-
iency. As such, there was no accelerated back diffu-
ion of the nonmetabolized radiotracer. However,
ecause carnitine is essential for the transport of
ong-chain fatty acids from the cytoplasm into the
atrix of mitochondria (the site of beta-oxidation),
ecreased carnitine availability results in longer resi-
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222dence of free fatty acids in the cytoplasm (in the form
of 123I-BMIPP coenzyme A), as reflected by the lower
washout rate of the radiotracer before carnitine ad-
ministration. These findings are supported by the
experimental observation in rats exhibiting prolonged
retention of 123I-BMIPP in the myocardium when
pretreated with a mitochondrial carnitine acyltrans-
ferase I inhibitor (83).
NewHorizons
Metabolomics. Our current knowledge of the dy-
amics of intermediary metabolism remains frag-
ented and poorly integrated into the biology of
he cell. The new and powerful tools of systems
iology give a fresh approach to the diagnosis and
reatment of different forms of heart disease. A case
n point is the field of metabolomics. In analogy to
he genome, the transcriptome, and the proteome,
he metabolome has been defined as the total set of
ow molecular weight metabolites. The techniques
f metabolomics (in particular nuclear magnetic
esonance and mass spectroscopy) allow us to ana-
yze changes in the metabolome in a given system.
major advantage of this metabolic profiling is the
omparatively small number of possible targets: The
uman Metabolome Database currently lists ap-
roximately 7,900 small metabolites, compared
ith 25,000 genes, 100,000 transcripts, and
,000,000 proteins (84). Further, metabolites may
how a better correlation with a disease’s phenotype
han messenger ribonucleic acids or proteins, as
hey are further proximal reporters of a pathological
rocess. Recent studies have delivered promising
esults and reported new markers for the develop-
ent of type 2 diabetes (85) or coronary artery
isease and subsequent cardiovascular events (86).
Considering our hypothesis of metabolic changes
receding and triggering structural and functional
hanges in the heart, metabolomics can be useful
eyond the mere exploration of biomarkers and can
ssist the search for mediators of cardiovascular
iseases. However, the impact of changes in the
etabolome is debated and additional mechanistic
tudies would be needed to define the biological
elevance of such changes. Although the use of
etabolomics for assessing cardiovascular diseases
s still in its infancy, it may soon be a powerful tool
n the quest for alterations in metabolite levels and
etermining their pathophysiological impact.
Tracking the fate of transplanted stem cells. Myocar-
ial regeneration through stem cell injection is a
eguiling concept, which to date has producedixed results. Laboratory experiments and clinical
rials suggest that cell-based therapies can improve
ardiac function (87). Several experimental strate-
ies to “remuscularize” and revascularize the failing
eart using adult stem cells or pluripotent stem
ells, cellular reprogramming, or tissue engineering
re in progress and offer unique opportunities for
etabolic imaging.
After MI, patients have a high risk of developing
eart failure due to cardiomyocyte death. Although
he current treatments of MI aim to reduce the
xtent of cell death in the heart, they cannot restore
yocardial contractility. With a cell-based therapy,
yocytes can be generated out of adult, autolo-
ously transplanted stem cells and, therefore, pre-
ent the progression into heart failure. Whereas the
ecent development in the field of stem cell therapy
s out of the scope of this review, it is appropriate to
omment on using imaging techniques to track
ransplanted stem cells in vivo. Although pre-
linical studies have delivered promising data, con-
erns about dose requirements, localization after
njection, as well as viability impede the clinical use
f autologously transplanted stem cells. All of these
spects can be assessed with the help of noninvasive
maging techniques.
In general, stem cells can be tracked with differ-
nt imaging methods such as cardiac magnetic
esonance imaging, PET, and SPECT. Further,
ultimodality approaches, combining PET or
PECT with cardiac magnetic resonance imaging
r computed tomography, merge the advantages
nd datasets delivered by each imaging technique
tself (88). Stem cells can be labeled with radioactive
arkers before transplantation to assess their local-
zation in the host’s body. However, concerns about
he dissociation of the radionuclide from the stem
ell have questioned the reliability of this technique
or long-time studies, although it is a valid method
o determine the success of a transplantation di-
ectly after delivery (88). Nonetheless, metabolic
maging of stem cells with 18F-FDG has produced
romising results tracking the homing of cluster of
ifferentiation CD34 cells to infarcted myocar-
dium (Fig. 6) (89). A different labeling technique
uses reporter genes that are introduced into the stem
cells or the host genome. Beside the ability to perform
long-time studies, the use of reporter genes allows the
investigator or clinician to assess stem cell survival, as
only viable cells produce the reporter probe. A recent
study by Lee et al. (90) has demonstrated the appli-
cability of these techniques in a large-animal model.
Briefly, the investigators generated induced pluripo-
g
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223tent stem cells (iPSC) from adipose stromal cells in a
canine model and transduced these iPSC with a
triple-fusion reporter gene that included the herpes
simplex truncated thymidine kinase. After injection of
9-[4-[(18)F]fluoro-3(hydroxymethyl)butyl]guanine,
they could determine the accumulation of iPSC (as
increased tracer activity) in the anterior wall and
confirm its localization by cardiac magnetic resonance
imaging and colabeling of iPSC with iron-oxide
particles. Improving stem cell targeting and reparative
capacity will also rely heavily on metabolic imaging
with PET in the future (91). Although the usefulness
of this strategy is beyond question, little work has been
done in this area until now.
Conclusions
In recent years, the tools of molecular and cellular
biology have provided new insights into the com-
Figure 6. Myocardial Homing and Biodistribution of 18F-FDG–La
Left posterior oblique (A) and left anterior oblique (B) views of che
18F-FDG–labeled, unselected bone marrow cells (BMC) into left circu
the heart (infarct center and border zone), liver, and spleen. Left po
upper abdomen of Patient #7 taken 70 min after transfer of 18F-FD
rior descending coronary artery. Homing of CD34-enriched cells is d
CD34 cell homing is most prominent in infarct border zone (arrow
from Hofmann et al. (89). Abbreviation as in Figure 4.plex mechanisms of metabolic pathways and the Emultitude of potential targets that can be explored
for the treatment of various heart diseases. SPECT
and PET imaging techniques provide a sensitive,
noninvasive, quantitative tool for investigating pre-
clinical and clinical abnormalities in myocardial
perfusion, metabolism, enzymatic, or receptor de-
rangements and allow for monitoring disease pro-
gression and the effectiveness of medical therapy.
The new fields of metabolomics and stem cell
imaging offer challenges to both the experimental
biologist and the clinical cardiologist to refine the
tools of metabolic imaging for the diagnosis and
treatment of myocardial diseases.
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